Max Nisen

Columnist

Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.

Insurance

Benefits Think Cigna-Express Scripts deal leaves rivals in the lurch

The health-care industry's game of musical chairs just got more intense and more expensive.

By Max Nisen

March 8

Healthcare-related legislation

Benefits Think The ACA replacement plan is already dead

The proposed bill cuts taxes for wealthy people, ends Medicaid as we know it to help pay for those tax cuts, reduces the number of Americans who can afford health insurance, and angers such a wide variety of voting constituencies that it is effectively dead on arrival, writes Bloomberg Gadfly Columnist Max Nisen.

By Max Nisen

March 8

Obamacare

Benefits Think Aetna’s ACA brushback is part of the game

The insurer warned the government in a July letter that it would be financially forced to step back its participation in the individual insurance exchanges if the DOJ tried to block its $28 billion purchase of Humana. Guess what happened, writes Max Nisen.

By Max Nisen

August 18

M&A

Benefits Think Anthem-Cigna’s market doubters have a point

Investors have never been sold on either deal as a sure thing, but the Anthem-Cigna tie-up is looking increasingly endangered, writes Bloomberg Gadfly's Max Nisen.

By Max Nisen

May 25